Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15644526 | 0.87 | TSPO (0.48) | TSPOALDH1A1KDM4EMAPTHSD17B10 | |
| SCHEMBL15643473 | 0.87 | TSPO (0.48) | TSPOALDH1A1KDM4EMAPTHSD17B10 | |
| SCHEMBL15643567 | 0.85 | APEX1 (0.63) | TSPOKDM4EHSD17B10KCNH2LMNA | |
| SCHEMBL15643214 | 0.83 | DRD2 (0.55) | ALDH1A1KDM4EMAPTHSD17B10NPC1 | |
| SCHEMBL15643536 | 0.83 | MAPT (0.65) | ALDH1A1KDM4EMAPTHSD17B10NPC1 | |
| SCHEMBL8268180 | 0.82 | KDM4E (0.67) | ALDH1A1KDM4EMAPTHSD17B10NPC1 | |
| SCHEMBL15643422 | 0.81 | DRD2 (0.77) | MAPTKCNH2DRD2TBXA2R | |
| SCHEMBL3580770 | 0.81 | KDM4E (0.65) | ALDH1A1KDM4EMAPTHSD17B10NPC1 | |
| SCHEMBL15643324 | 0.77 | KCNH2 (0.64) | TSPOALDH1A1KDM4EMAPTKCNH2 | |
| SCHEMBL15643334 | 0.75 | AGTR1 (0.66) | MAPTKCNH2KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140114067-A1 | BENZIMIDAZOLE DERIVATIVES AS MITOCHONDRIAL FUNCTION MODULATORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140114067-A1 | BENZIMIDAZOLE DERIVATIVES AS MITOCHONDRIAL FUNCTION MODULATORS | NLN, TFAM, NDUFAB1 | TSPO 183/4885ALDH1A1 1199/4885KDM4E 2912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.